Meet the Biopharma Research Team

Brian Abrahams, M.D.

Brian Abrahams, M.D.

Managing Director, Co-Head of Biotechnology Research

Dr. Brian Abrahams joined RBC Capital Markets in July 2017 as a senior analyst covering the biotechnology sector. He has 15 years of experience following large, mid, and small cap biotech companies, and prior to RBC spent time in biotechnology equity research at Jefferies, Wells Fargo, and CIBC World Markets / Oppenheimer & Co. He is a licensed non-practicing physician and holds a medical degree from the Albert Einstein College of Medicine. He did his undergraduate studies at Yale University, where he graduated magna cum laude with a Bachelor of Science degree in Molecular Biophysics & Biochemistry.

Kennen MacKay, Ph.D.

Kennen MacKay, Ph.D.

Managing Director, Co-Head of Biotechnology Research

Dr. Kennen MacKay is a Managing Director at RBC and Co-Head of RBC Biotechnology Research. Kennen has over 10 years of biotechnology experience and previously covered the biotechnology sector at Credit Suisse and Citigroup. Prior to his career on Wall St., Kennen served as Director of the Michelson Prize and Grants under Los Angeles billionaire Dr. Gary Michelson, where he vetted biotechnologies for development in the non-profit setting. Kennen received his Ph.D. in Biochemistry and Molecular Biology from UCLA and his BA in Biochemistry from Colorado College, where he was a 4-yr Academic All-American on the swim team.

Luca Issi, Ph.D.

Luca Issi, Ph.D.

Senior Biotechnology Research Analyst

Luca Issi joined RBC Capital Market in 2020, and is covering Biotech. Prior to RBC, he was an investor at Bain Capital Life Sciences, where he led private and public investments across biopharmaceutical, medical device, specialty pharma and tools & diagnostics. Prior to Bain, he worked in equity research at Cowen and Company, where he covered large cap pharmaceutical companies. He received his PhD in Biotechnology from Worcester Polytechnic Institute and graduated summa cum laude in Biotechnology from the University of Milan (MS) and the University of Varese (BS).

Gregory Renza, M.D.

Gregory Renza, M.D.

Senior Biotechnology Research Analyst

Dr. Gregory Renza is a Director and Senior Analyst of Biotechnology Equity Research at RBC Capital Markets, joining the firm in  2017. Previously, he served on the biotechnology equity research team at Jefferies as well as the specialty pharmaceuticals equity research team at Wells Fargo Securities.  Prior to equity research, Greg worked in management consulting at Booz & Company (now Strategy& at PwC) and in strategy at CVS Caremark (now CVS Health).  Greg holds an A.B. in Biology from Brown University and an M.D. from Brown University’s Warren Alpert Medical School.

Randall Stanicky

Randall Stanicky

Large cap, Specialty and Generic Pharmaceuticals Research Analyst

Randall brings more than 20 years of experience to his role as lead analyst of RBC Capital Markets' Large cap, Specialty and Generic pharmaceuticals research team in New York with coverage of over 20 stocks. Randall joined our firm in 2013 following his tenure at Goldman Sachs and Canaccord Genuity, where he provided of the same sector. Prior to becoming a sell-side analyst, Randall followed healthcare stocks on the buy side at Citigroup Global Asset Management. Randall received a bachelor's degree in commerce from the University of British Columbia and he is a CFA charterholder and currently sits on the Board of Directors at the Children's Tumor Foundation. Randall is a Managing Director of RBC Capital Markets.

Subscribe Today

Get the latest insights from RBC Capital Markets delivered to your inbox.